Industry News

Permira acquires Neuraxpharm from Apax Partners

September 23rd, 2020

Permira acquires Neuraxpharm from Apax Partners

Neuraxpharm is a European specialty pharmaceutical company, focused on the treatment of the central nervous system (CNS).They develop and commercialise value-added medicines and consumer healthcare products for chronic patients suffering from neurological and psychiatric disorders including Epilepsy, Parkinson’s, Alzheimer’s, Depression and Psychosis. With its core markets in Germany and Spain, the company has annual revenues in excess of €460 million and 850 employees.

Dr. Jörg Rockenhäuser, Head of DACH at Permira, said: “We are very excited to join forces with Neuraxpharm. The team led by CEO Dr. Jörg-Thomas Dierks has built one of the most relevant European players in the CNS field. With our longstanding global track-record in successfully transforming market leaders and our proven expertise in the healthcare sector, the Permira funds will back Neuraxpharm to reach the next level of growth. Our joint goal is to create the leading European CNS specialty platform with further acquisitions and strong organic growth. This transaction also marks an excellent start for our strengthened DACH healthcare team, led by Florian Kreuzer who joined Permira a year ago.”

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, added: “We are very pleased to be partnering with Permira who are perfectly placed to support us in the next phase of our exciting journey given their experience of investing in healthcare and high-growth companies. Together we will drive further geographical expansion and strengthen our position as the leading CNS specialist. I would like to thank Apax Partners for the great partnership over the last four years, during which time we internationalised, invested significantly into our product pipeline and created a pan-European platform to support rapid and sustainable growth.”

Share this article
© Copyright 2024